Atea Pharmaceuticals Correlations
AVIR Stock | USD 3.22 0.07 2.22% |
The current 90-days correlation between Atea Pharmaceuticals and Immix Biopharma is 0.18 (i.e., Average diversification). The correlation of Atea Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak. If the correlation is 0, the equities are not correlated; they are entirely random.
Atea Pharmaceuticals Correlation With Market
Average diversification
The correlation between Atea Pharmaceuticals and DJI is 0.16 (i.e., Average diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Atea Pharmaceuticals and DJI in the same portfolio, assuming nothing else is changed.
Atea |
Moving together with Atea Stock
0.68 | VINC | Vincerx Pharma Earnings Call This Week | PairCorr |
0.64 | ZURA | Zura Bio Limited | PairCorr |
0.66 | IMMX | Immix Biopharma | PairCorr |
0.73 | IMRX | Immuneering Corp | PairCorr |
0.63 | INBX | Inhibrx Symbol Change | PairCorr |
0.62 | ASMB | Assembly Biosciences Earnings Call This Week | PairCorr |
Moving against Atea Stock
0.57 | AZN | AstraZeneca PLC ADR | PairCorr |
0.57 | LLY | Eli Lilly | PairCorr |
0.57 | SNY | Sanofi ADR | PairCorr |
0.55 | GILD | Gilead Sciences | PairCorr |
0.44 | BMY | Bristol Myers Squibb Aggressive Push | PairCorr |
0.38 | PLX | Protalix Biotherapeutics | PairCorr |
0.34 | OCX | OncoCyte Corp | PairCorr |
0.62 | AMGN | Amgen Inc | PairCorr |
0.61 | DRMAW | Dermata Therapeutics | PairCorr |
0.56 | CMPX | Compass Therapeutics | PairCorr |
0.32 | REPL | Replimune Group | PairCorr |
Related Correlations Analysis
Click cells to compare fundamentals | Check Volatility | Backtest Portfolio |
Correlation Matchups
Over a given time period, the two securities move together when the Correlation Coefficient is positive. Conversely, the two assets move in opposite directions when the Correlation Coefficient is negative. Determining your positions' relationship to each other is valuable for analyzing and projecting your portfolio's future expected return and risk.High positive correlations
| High negative correlations
|
Risk-Adjusted Indicators
There is a big difference between Atea Stock performing well and Atea Pharmaceuticals Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Atea Pharmaceuticals' multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.Mean Deviation | Jensen Alpha | Sortino Ratio | Treynor Ratio | Semi Deviation | Expected Shortfall | Potential Upside | Value @Risk | Maximum Drawdown | ||
---|---|---|---|---|---|---|---|---|---|---|
IMMX | 3.38 | (0.09) | 0.00 | (8.37) | 0.00 | 6.82 | 26.42 | |||
CNSP | 5.71 | (0.05) | 0.00 | (0.19) | 0.00 | 12.10 | 70.89 | |||
HEPA | 9.87 | (3.91) | 0.00 | (5.38) | 0.00 | 16.37 | 90.05 | |||
FRLN | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
AVRO | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
ENVB | 7.01 | (0.69) | 0.00 | (0.52) | 0.00 | 12.04 | 113.38 | |||
CWBR | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||
ELEV | 5.06 | (0.69) | 0.00 | (0.53) | 0.00 | 8.33 | 68.94 | |||
OCEA | 7.12 | (3.00) | 0.00 | (1.94) | 0.00 | 15.38 | 51.00 | |||
EFTR | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Atea Pharmaceuticals Corporate Management
CPA CPA | Exec Officer | Profile | |
XiaoJian Zhou | Executive Development | Profile | |
Jayanthi Wolf | Executive Affairs | Profile | |
Wayne CPA | Executive Officer | Profile | |
Ariyapadi Krishnaraj | Vice Marketing | Profile | |
JeanPierre Sommadossi | Chairman, Founder | Profile | |
John Vavricka | Chief Officer | Profile |